The L.A. Times has the story of Ascenta Therapeutics, which has been tapping scientists at a facility in China to advance its drug prospects while keeping R&D budgets in line. According to the Times, the experts see Ascenta as something of a test case, blazing a trail in China that other smaller developers are likely to follow. China has some tough competition in India and Eastern Europe. That's one reason why government officials have aggressively attacked corruption at China's FDA, recently sentencing the former head of the Chinese agency to death for accepting bribes.
- here's the article from The Los Angeles Times
Ascenta gins $50M in third round. Report
China says former drug czar accepted bribes. Report
China's future in the biotech industry. Editorial
Bridge Pharma sees growth in China drug studies. Report